Mitigating temozolomide resistance in glioblastoma via DNA damage-repair inhibition.
alkylpurine-DNA-N-glycosylase
glioblastoma
mathematical model
methylguanine-DNA-methyltransferase
temozolomide
Journal
Journal of the Royal Society, Interface
ISSN: 1742-5662
Titre abrégé: J R Soc Interface
Pays: England
ID NLM: 101217269
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
entrez:
23
1
2020
pubmed:
23
1
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
Glioblastomas are among the most lethal cancers, with a 5 year survival rate below 25%. Temozolomide is typically used in glioblastoma treatment; however, the enzymes alkylpurine-DNA-
Identifiants
pubmed: 31964274
doi: 10.1098/rsif.2019.0722
pmc: PMC7014791
doi:
Substances chimiques
Dacarbazine
7GR28W0FJI
Temozolomide
YF1K15M17Y
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20190722Références
Am J Clin Pathol. 2003 Dec;120(6):902-8
pubmed: 14671979
Bioinformatics. 2018 Apr 15;34(8):1421-1423
pubmed: 29206901
CA Cancer J Clin. 2014 Mar-Apr;64(2):83-103
pubmed: 24488779
PLoS One. 2017 Jun 29;12(6):e0178693
pubmed: 28662073
Neuroimage. 2007;37 Suppl 1:S59-70
pubmed: 17475515
Brief Bioinform. 2018 Mar 1;19(2):263-276
pubmed: 27881431
Cell Death Dis. 2013 Oct 24;4:e876
pubmed: 24157870
Oncogene. 2003 Jun 26;22(26):3985-91
pubmed: 12821932
Genes Dis. 2016 May 11;3(3):198-210
pubmed: 30258889
Front Oncol. 2012 Aug 14;2:98
pubmed: 22912934
FASEB J. 2008 Sep;22(9):3196-206
pubmed: 18509200
Ann Neurol. 2011 Jul;70(1):9-21
pubmed: 21786296
Cancer Treat Rev. 1997 Jan;23(1):35-61
pubmed: 9189180
J Clin Invest. 2012 Jan;122(1):253-66
pubmed: 22156195
Cell Prolif. 1995 Jan;28(1):17-31
pubmed: 7833383
Trends Mol Med. 2006 Sep;12(9):440-50
pubmed: 16899408
J Pharmacol Exp Ther. 2005 Nov;315(2):526-33
pubmed: 16081682
Adv Pharm Bull. 2014 Dec;4(4):313-21
pubmed: 25436185
Lancet Oncol. 2012 Sep;13(9):916-26
pubmed: 22877848
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Front Oncol. 2015 Mar 03;5:55
pubmed: 25785247
Neuro Oncol. 2017 Nov 6;19(suppl_5):v1-v88
pubmed: 29117289
Neuro Oncol. 2009 Feb;11(1):69-79
pubmed: 18772354
Cell. 2017 Nov 30;171(6):1437-1452.e17
pubmed: 29195078
Clin Cancer Res. 2007 Jan 1;13(1):260-7
pubmed: 17200364
J R Soc Interface. 2017 Nov;14(136):
pubmed: 29118112
Cancer Res. 2001 Aug 1;61(15):5843-9
pubmed: 11479224
Math Biosci Eng. 2012 Oct;9(4):843-76
pubmed: 23311425
J Neurol Sci. 2003 Dec 15;216(1):1-10
pubmed: 14607296
J Neurochem. 2018 Mar;144(6):780-790
pubmed: 29480969
J Theor Biol. 2008 Sep 7;254(1):178-96
pubmed: 18572196
Clin Exp Med. 2013 Nov;13(4):279-88
pubmed: 22828727
Future Med Chem. 2012 Jun;4(9):1093-111
pubmed: 22709253
CPT Pharmacometrics Syst Pharmacol. 2014 Apr 30;3:e112
pubmed: 24785551
J Neurooncol. 2012 May;108(1):11-27
pubmed: 22270850
Neuro Oncol. 2009 Jun;11(3):281-91
pubmed: 18952979
Genet Mol Biol. 2010 Jan;33(1):17-22
pubmed: 21637599
J Neurooncol. 2016 Aug;129(1):139-46
pubmed: 27300524
Biophys J. 2019 Apr 23;116(8):1560-1574
pubmed: 30979548
Cancer Res. 2000 Feb 1;60(3):566-72
pubmed: 10676638
Front Oncol. 2018 Feb 12;8:23
pubmed: 29484285
BMC Cancer. 2013 Mar 22;13:147
pubmed: 23522185
Cancer Res. 2007 Apr 15;67(8):3970-5
pubmed: 17440113
Biochim Biophys Acta. 2011 Dec;1816(2):179-90
pubmed: 21745538
Nat Rev Cancer. 2017 Apr;17(4):254-268
pubmed: 28104906
CNS Oncol. 2014 Jul;3(4):287-98
pubmed: 25286040
Clin Cancer Res. 2018 Mar 1;24(5):1124-1137
pubmed: 29254993
J Theor Biol. 2017 Oct 27;431:63-78
pubmed: 28733187
J Biomed Biotechnol. 2012;2012:760679
pubmed: 22496614
Clin Transl Oncol. 2018 Jan;20(1):22-28
pubmed: 29086250
Glia. 2005 Apr 15;50(2):107-20
pubmed: 15657940
Bioinformatics. 2003 Jan 22;19(2):185-93
pubmed: 12538238
Nat Biotechnol. 2014 Dec;32(12):1213-22
pubmed: 25419740
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Neuro Oncol. 2015 Oct;17(10):1402-11
pubmed: 25758748
J Clin Oncol. 2001 Apr 15;19(8):2319-33
pubmed: 11304786